While genomic assays offer significant benefits, they also have limitations. One major limitation is the potential for false positives or negatives, which can lead to inappropriate treatment decisions. Additionally, not all genetic mutations identified by these assays have targeted therapies available, which can limit their clinical utility. Cost and access to these advanced technologies can also be barriers for some patients.
